Merrimack completes patient enrolment in one cohort of Phase 2 study into breast cancer agent

Biopharmaceutical company Merrimack Pharmaceuticals has completed patient enrolment in one group of a two-cohort randomised Phase 2 study of MM-121 in HER2-negative breast cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news